| 1.14 0.05 (4.59%) | 11-20 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | ||||
| Targets | 6-month : | 1.4 | 1-year : | 1.63 |
| Resists | First : | 1.2 | Second : | 1.4 |
| Pivot price | 1.07 |
|||
| Supports | First : | 0.95 | Second : | 0.8 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 1.08 |
| MA(100) : | 1.26 |
MA(250) : | 1.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 79.1 |
D(3) : | 69.2 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 1.66 | Low : | 0.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VANI ] has closed below upper band by 14.1%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 1.09 - 1.09 | 1.09 - 1.1 |
| Close: | 1.13 - 1.14 | 1.14 - 1.15 |
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Fri, 20 Nov 2026
A correction identifies a 99,010-share trade in Vivani Medical (VANI) as a purchase at $1.01 per share. - Stock Titan
Fri, 20 Nov 2026
Vivani Medical (NASDAQ:VANI) Stock: Insider Gregg Williams Acquires 33,169 Shares - MarketBeat
Fri, 20 Nov 2026
Vivani Medical (VANI) director Williams bought 118,434 shares for $128K at an average $1.08 - Quantisnow
Fri, 20 Nov 2026
Vivani Medical, Inc. (VANI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 19 Nov 2026
A Vivani Medical (VANI) director’s 99,010-share trade is described as a purchase but marked as a disposition. - Stock Titan
Mon, 16 Nov 2026
Vivani Medical Announces Private Placement Equity Financing - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 55.3 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 417 (K) |
| Shares Short P.Month | 694 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.5 % |
| Return on Equity (ttm) | -220.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -3.17 |
| PEG Ratio | 0 |
| Price to Book value | 5.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |